SEC Form 4 · accession 0001609351-16-000033
Spark Therapeutics, Inc. · ONCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Faga
Officer — Chief Business Officer
Period of report
May 2, 2016
Accepted (ET)
May 4, 2016 · 4:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609351
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $37.62 | May 2, 2016 | A | 160,000 | A | — | May 1, 2026 | Common Stock | 160,000 | 160,000 | D |
Explanation of responses
- F125% vest on May 2, 2017 and the remainder vests in equal quarterly installments over the following three years.